Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pfizer Inc (PFE)

Pfizer Inc (PFE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 146,975,552
  • Shares Outstanding, K 5,685,708
  • Annual Sales, $ 63,627 M
  • Annual Income, $ 8,031 M
  • EBIT $ 18,723 M
  • EBITDA $ 25,736 M
  • 60-Month Beta 0.46
  • Price/Sales 2.31
  • Price/Cash Flow 5.91
  • Price/Book 1.58

Options Overview Details

View History
  • Implied Volatility 23.38% (+0.90%)
  • Historical Volatility 25.34%
  • IV Percentile 24%
  • IV Rank 15.13%
  • IV High 52.17% on 04/10/25
  • IV Low 18.25% on 08/18/25
  • Expected Move (DTE 5) 0.71 (2.76%)
  • Put/Call Vol Ratio 0.42
  • Today's Volume 141,048
  • Volume Avg (30-Day) 155,105
  • Put/Call OI Ratio 0.72
  • Today's Open Interest 3,473,689
  • Open Int (30-Day) 3,520,386
  • Expected Range 25.14 to 26.56

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.63
  • Number of Estimates 4
  • High Estimate 0.77
  • Low Estimate 0.55
  • Prior Year 0.63
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.28 +6.47%
on 11/20/25
26.48 -2.36%
on 11/13/25
-0.02 (-0.08%)
since 11/12/25
3-Month
23.58 +9.63%
on 09/25/25
27.69 -6.64%
on 10/03/25
+1.98 (+8.29%)
since 09/12/25
52-Week
20.92 +23.60%
on 04/09/25
27.69 -6.64%
on 10/03/25
+0.48 (+1.89%)
since 12/12/24

Most Recent Stories

More News
Pfizer Declares First-Quarter 2026 Dividend

Board of Directors approves quarterly cash dividend of $0.43 per share

PFE : 25.85 (+0.19%)
Covered Call Screener Results For Dec 10th

Covered calls are a great strategy to add to any portfolio, and can offer enhanced yield from stock holdings, in some case, that can be a significant increase.

XLF : 54.95 (+0.15%)
NEM : 98.14 (-1.29%)
MRK : 100.30 (+1.30%)
XOM : 118.82 (-0.60%)
PFE : 25.85 (+0.19%)
WMT : 116.70 (+1.02%)
TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer

TUKYSA, trastuzumab, and pertuzumab reduced the risk of disease progression or death by 36% compared to trastuzumab and pertuzumab alone in Phase 3 HER2CLIMB-05 study ...

PFE : 25.85 (+0.19%)
Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma

Augments Pfizer’s efforts to advance investigational medicines for cardiometabolic diseases

PFE : 25.85 (+0.19%)
HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors

Findings from the Phase 3 study were presented at the 67 th American Society of Hematology Annual Meeting and Exposition and published in Blood

PFE : 25.85 (+0.19%)
3 Low-Volatility Stocks with Warning Signs

3 Low-Volatility Stocks with Warning Signs

EXPO : 73.63 (+0.26%)
AFL : 110.05 (+1.10%)
PFE : 25.85 (+0.19%)
3 Reasons PFE is Risky and 1 Stock to Buy Instead

3 Reasons PFE is Risky and 1 Stock to Buy Instead

PFE : 25.85 (+0.19%)
U.S. and U.K. Reach Agreement in Principle on Pharmaceutical Pricing in New Economic Prosperity Deal

The United States and the United Kingdom have reached an agreement in principle on pharmaceutical pricing as part of the new U.S.–U.K. Economic Prosperity Deal, aimed at addressing long-standing pricing...

MRK : 100.30 (+1.30%)
PFE : 25.85 (+0.19%)
GSK : 48.81 (-0.14%)
Pfizer Invites Public to View and Listen to Webcast of December 16 Conference Call with Analysts to Provide Full-Year 2026 Financial Guidance

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 8:00 a.m. EST on Tuesday, December 16, 2025. The purpose...

PFE : 25.85 (+0.19%)
1 Profitable Stock on Our Buy List and 2 We Turn Down

1 Profitable Stock on Our Buy List and 2 We Turn Down

PAYO : 5.96 (+1.19%)
BCC : 76.51 (+0.33%)
PFE : 25.85 (+0.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare...

See More

Key Turning Points

3rd Resistance Point 26.34
2nd Resistance Point 26.19
1st Resistance Point 26.02
Last Price 25.85
1st Support Level 25.70
2nd Support Level 25.55
3rd Support Level 25.38

See More

52-Week High 27.69
Last Price 25.85
Fibonacci 61.8% 25.10
Fibonacci 50% 24.30
Fibonacci 38.2% 23.50
52-Week Low 20.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar